Urokinase-Receptor (u-PAR)–An Essential Player in Multiple Games of Cancer: A Review on Its Role in Tumor Progression, Invasion, Metastasis, Proliferation/dormancy, Clinical Outcome and Minimal Residual Disease
暂无分享,去创建一个
[1] B. Schwartz,et al. Interaction of Single-chain Urokinase and Plasminogen Activator Inhibitor Type 1 (*) , 1995, The Journal of Biological Chemistry.
[2] F. Ali-Osman,et al. Modulation of in vitro invasion of human glioblastoma cells by urokinase-type plasminogen activator receptor antibody. , 1993, Cancer research.
[3] W. Birchmeier,et al. Epithelial-mesenchymal transitions in cancer progression. , 1996, Acta anatomica.
[4] O. Majdic,et al. Molecular and Functional Characterization of the Urokinase Receptor on Human Mast Cells* , 1997, The Journal of Biological Chemistry.
[5] B. M. Mueller,et al. The urokinase-type plasminogen activator receptor, a GPI-linked protein, is localized in caveolae , 1995, The Journal of cell biology.
[6] H. Höfler,et al. Modulation of urokinase and urokinase receptor gene expression in human renal cell carcinoma. , 1995, The American journal of pathology.
[7] F. Blasi,et al. Protease nexin-1-urokinase complexes are internalized and degraded through a mechanism that requires both urokinase receptor and alpha 2-macroglobulin receptor. , 1994, The Journal of biological chemistry.
[8] K. Pantel,et al. Immunocytochemical detection of disseminated tumor cells in the bone marrow of patients with esophageal carcinoma. , 1996, Journal of the National Cancer Institute.
[9] Hua Tang,et al. The Urokinase-type Plasminogen Activator Receptor Mediates Tyrosine Phosphorylation of Focal Adhesion Proteins and Activation of Mitogen-activated Protein Kinase in Cultured Endothelial Cells* , 1998, The Journal of Biological Chemistry.
[10] G. Sauter,et al. Expression of Extracellular Matrix Metalloproteases Inducer on Micrometastatic and Primary Mammary Carcinoma Cells , 2004, Clinical Cancer Research.
[11] J. Izbicki,et al. Methodological analysis of immunocytochemical screening for disseminated epithelial tumor cells in bone marrow. , 1994, Journal of hematotherapy.
[12] Michael V. Doyle,et al. Regulation of Integrin Function by the Urokinase Receptor , 1996, Science.
[13] Anne Vincent-Salomon,et al. Clinical Significance of Immunocytochemical Detection of Tumor Cells Using Digital Microscopy in Peripheral Blood and Bone Marrow of Breast Cancer Patients , 2004, Clinical Cancer Research.
[14] H. Allgayer,et al. Identification of a novel nuclear factor-kappaB sequence involved in expression of urokinase-type plasminogen activator receptor. , 2000, European journal of biochemistry.
[15] A. Corti,et al. Differentiation-enhanced binding of the amino-terminal fragment of human urokinase plasminogen activator to a specific receptor on U937 monocytes. , 1985, Proceedings of the National Academy of Sciences of the United States of America.
[16] T. Dimpfl,et al. Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II, or III breast cancer. , 2000, The New England journal of medicine.
[17] J. Foekens,et al. Enhanced benefit from adjuvant chemotherapy in breast cancer patients classified high-risk according to urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (n = 3424). , 2002, Cancer research.
[18] H. Höfler,et al. Primary tumor and metastasis in ovarian cancer differ in their content of urokinase-type plasminogen activator, its receptor, and inhibitors types 1 and 2. , 1995, Cancer research.
[19] Ruud H. Brakenhoff,et al. Dissecting the metastatic cascade , 2004, Nature Reviews Cancer.
[20] S. Capaccioli,et al. Reversion of the invasive phenotype of transformed human fibroblasts by anti-messenger oligonucleotide inhibition of urokinase receptor gene expression. , 1995, Cancer research.
[21] N. Colburn,et al. Differentially expressed protein Pdcd4 inhibits tumor promoter-induced neoplastic transformation. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[22] F. Blasi,et al. Proteolytic cleavage of the urokinase receptor substitutes for the agonist‐induced chemotactic effect. , 1996, The EMBO journal.
[23] S. Braun,et al. Biological characteristics of micrometastatic carcinoma cells in bone marrow. , 1996, Current topics in microbiology and immunology.
[24] W. Schleuning,et al. Isolation and characterization of urokinase from human plasma. , 1982, The Journal of biological chemistry.
[25] C. Gondi,et al. Specific Interference of Urokinase-type Plasminogen Activator Receptor and Matrix Metalloproteinase-9 Gene Expression Induced by Double-stranded RNA Results in Decreased Invasion, Tumor Growth, and Angiogenesis in Gliomas* , 2005, Journal of Biological Chemistry.
[26] A. Ménez,et al. Crystal structure of the human urokinase plasminogen activator receptor bound to an antagonist peptide , 2005, The EMBO journal.
[27] M. Duffy. The role of proteolytic enzymes in cancer invasion and metastasis , 1992, Clinical & Experimental Metastasis.
[28] E. Lengyel,et al. Elevated urokinase-type plasminogen activator receptor expression in a colon cancer cell line is due to a constitutively activated extracellular signal-regulated kinase-1-dependent signaling cascade , 1997, Oncogene.
[29] H. Verspaget,et al. Urokinase receptor and colorectal cancer survival , 1994, The Lancet.
[30] I. Funke,et al. Meta-analyses of studies on bone marrow micrometastases: an independent prognostic impact remains to be substantiated. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[31] Zhimin Lu,et al. RalA requirement for v-Src- and v-Ras-induced tumorigenicity and overproduction of urokinase-type plasminogen activator: involvement of metalloproteases , 1999, Oncogene.
[32] D. Boyd. Examination of the effects of epidermal growth factor on the production of urokinase and the expression of the plasminogen activator receptor in a human colon cancer cell line. , 1989, Cancer research.
[33] S. Braun,et al. The fate and prognostic value of occult metastatic cells in the bone marrow of patients with breast carcinoma between primary treatment and recurrence , 2001, Cancer.
[34] M. Osborne,et al. Detection and management of bone marrow micrometastases in breast cancer. , 1994, Oncology.
[35] Y. Kook,et al. The effect of antisense inhibition of urokinase receptor in human squamous cell carcinoma on malignancy. , 1994, The EMBO journal.
[36] P. Farnham,et al. Transcription initiation from the dihydrofolate reductase promoter is positioned by HIP1 binding at the initiation site , 1990, Molecular and cellular biology.
[37] M. Clark,et al. Cloning and expression of a cDNA coding for a human monocyte-derived plasminogen activator inhibitor. , 1988, Proceedings of the National Academy of Sciences of the United States of America.
[38] H. Allgayer,et al. Transactivation of the Urokinase-type Plasminogen Activator Receptor Gene through a Novel Promoter Motif Bound with an Activator Protein-2α-related Factor* , 1999, The Journal of Biological Chemistry.
[39] S. Braun,et al. Immunocytochemical double staining of cytokeratin and prostate specific antigen in individual prostatic tumour cells , 2004, Histochemistry.
[40] D. Boyd,et al. Transgenic mice demonstrate novel promoter regions for tissue-specific expression of the urokinase receptor gene. , 2003, The American journal of pathology.
[41] T. Reimer,et al. Simultaneous immunohistochemical detection of tumor cells in lymph nodes and bone marrow aspirates in breast cancer and its correlation with other prognostic factors. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[42] Jian-ning Liu,et al. Urokinase-type Plasminogen Activator-induced Monocyte Adhesion Requires a Carboxyl-terminal Lysine and cAMP-dependent Signal Transduction (*) , 1995, The Journal of Biological Chemistry.
[43] D. Easton,et al. Bone marrow micrometastases in primary breast cancer: prognostic significance after 6 years' follow-up. , 1991, European journal of cancer.
[44] K. Helin,et al. A conserved TATA-less proximal promoter drives basal transcription from the urokinase-type plasminogen activator receptor gene. , 1995, Blood.
[45] M. Duffy,et al. Urokinase-plasminogen activator, a new and independent prognostic marker in breast cancer. , 1990, Cancer research.
[46] F. Blasi. Surface Receptors for Urokinase Plasminogen Activator , 1988 .
[47] L. Ossowski,et al. Reduction in Surface Urokinase Receptor Forces Malignant Cells into a Protracted State of Dormancy , 1997, The Journal of cell biology.
[48] T. Fehm,et al. Epithelial cells in bone marrow of breast cancer patients at time of primary surgery: clinical outcome during long-term follow-up. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[49] J. Izbicki,et al. Disseminated tumor cells in lymph nodes as a determinant for survival in surgically resected non-small-cell lung cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[50] T. Urano,et al. Cancer cells overexpress mRNA of urokinase‐type plasminogen activator, its receptor and inhibitors in human non‐small‐cell lung cancer tissue: Analysis by Northern blotting and in situ hybridization , 1998, International journal of cancer.
[51] H. Allgayer,et al. Stimulation of urokinase-type plasminogen activator receptor expression by PMA requires JNK1-dependent and -independent signaling modules , 1998, Oncogene.
[52] S. Braun,et al. Minimal residual epithelial cancer: diagnostic approaches and prognostic relevance. , 1996, Progress in histochemistry and cytochemistry.
[53] J. Millán,et al. Cloning and sequence of a cDNA coding for the human beta-migrating endothelial-cell-type plasminogen activator inhibitor. , 1986, Proceedings of the National Academy of Sciences of the United States of America.
[54] S. Shetty,et al. Posttranscriptional regulation of urokinase receptor mRNA: identification of a novel urokinase receptor mRNA binding protein in human mesothelioma cells , 1997, Molecular and cellular biology.
[55] C. Gondi,et al. RNA interference-directed knockdown of urokinase plasminogen activator and urokinase plasminogen activator receptor inhibits prostate cancer cell invasion, survival, and tumorigenicity in vivo. , 2006, The Journal of biological chemistry.
[56] H. Allgayer,et al. Combination Analysis of Activator Protein-1 Family Members, Sp1 and an Activator Protein-2α-Related Factor Binding to Different Regions of the Urokinase Receptor Gene in Resected Colorectal Cancers , 2005, Clinical Cancer Research.
[57] H. Dvorak. Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. , 1986, The New England journal of medicine.
[58] C. Zandonella,et al. Urokinase receptor antagonists inhibit angiogenesis and primary tumor growth in syngeneic mice. , 1996, Cancer research.
[59] P. Carroll,et al. Low frequency epithelial cells in bone marrow aspirates from prostate carcinoma patients are cytogenetically aberrant , 1998, Cancer.
[60] H. Allgayer,et al. Tumor-specific transcription factor binding to an activator protein-2/Sp1 element of the urokinase-type plasminogen activator receptor promoter in a first large series of resected gastrointestinal cancers. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[61] H. Sather,et al. Prognostic value of immunocytologic detection of bone marrow metastases in neuroblastoma. , 1991, The New England journal of medicine.
[62] G. Cassani,et al. Binding of single-chain prourokinase to the urokinase receptor of human U937 cells. , 1986, The Journal of biological chemistry.
[63] M. Duffy,et al. The urokinase‐type plasminogen activator system in cancer metastasis: A review , 1997, International journal of cancer.
[64] M. Cubellis,et al. Receptor‐mediated internalization and degradation of urokinase is caused by its specific inhibitor PAI‐1. , 1990, The EMBO journal.
[65] H. Petty,et al. Physical association of complement receptor type 3 and urokinase-type plasminogen activator receptor in neutrophil membranes. , 1994, Journal of immunology.
[66] L. Lund,et al. The receptor for urokinase-type plasminogen activator is expressed by keratinocytes at the leading edge during re-epithelialization of mouse skin wounds. , 1994, The Journal of investigative dermatology.
[67] N. Brünner,et al. Expression of uPA and its receptor by both neoplastic and stromal cells during xenograft invasion , 1994, International journal of cancer.
[68] H. Petty,et al. Urokinase-type plasminogen activator receptors associate with beta1 and beta3 integrins of fibrosarcoma cells: dependence on extracellular matrix components. , 1997, Cancer research.
[69] L. Bolund,et al. Assignment of the urokinase-type plasminogen activator receptor gene (PLAUR) to chromosome 19q13.1-q13.2. , 1992, American journal of human genetics.
[70] L. Flohé,et al. The primary structure of high molecular mass urokinase from human urine. The complete amino acid sequence of the A chain. , 1982, Hoppe-Seyler's Zeitschrift fur physiologische Chemie.
[71] H. Allgayer,et al. Transcriptional Induction of the Urokinase Receptor Gene by a Constitutively Active Src , 1999, The Journal of Biological Chemistry.
[72] S. Braun,et al. Occult tumor cells in bone marrow of patients with locoregionally restricted ovarian cancer predict early distant metastatic relapse. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[73] D. Boyd,et al. Role of the urokinase receptor in facilitating extracellular matrix invasion by cultured colon cancer. , 1991, Cancer research.
[74] P. Carmeliet,et al. Generation and characterization of urokinase receptor-deficient mice. , 1996, The Journal of clinical investigation.
[75] E. Appella,et al. Autocrine saturation of pro-urokinase receptors on human A431 cells , 1986, Cell.
[76] L. Ossowski,et al. In vivo invasion of modified chorioallantoic membrane by tumor cells: the role of cell surface-bound urokinase , 1988, The Journal of cell biology.
[77] K. Pantel,et al. RT‐PCR‐Based Detection of Occult Disseminated Tumor Cells in Peripheral Blood and Bone Marrow of Patients with Solid Tumors: An Overview , 2000, Annals of the New York Academy of Sciences.
[78] D. Boyd,et al. Requirement of an Upstream AP-1 Motif for the Constitutive and Phorbol Ester-inducible Expression of the Urokinase-type Plasminogen Activator Receptor Gene* , 1996, The Journal of Biological Chemistry.
[79] D. Boyd,et al. Examination of the role of the urokinase receptor in human colon cancer mediated laminin degradation. , 1989, Cancer research.
[80] H. Höfler,et al. Urokinase (uPA) and its inhibitor PAI-1 are strong and independent prognostic factors in node-negative breast cancer , 2005, Breast Cancer Research and Treatment.
[81] W. Yu,et al. Requirement for Specific Proteases in Cancer Cell Intravasation as Revealed by a Novel Semiquantitative PCR-Based Assay , 1998, Cell.
[82] H. Kessler,et al. Combination of an Src Kinase Inhibitor with a Novel Pharmacological Antagonist of the Urokinase Receptor Diminishes in Vitro Colon Cancer Invasiveness , 2004, Clinical Cancer Research.
[83] T. Ludwig. Local proteolytic activity in tumor cell invasion and metastasis. , 2005, BioEssays : news and reviews in molecular, cellular and developmental biology.
[84] L. Ellis,et al. Targeting of urokinase plasminogen activator receptor in human pancreatic carcinoma cells inhibits c-Met- and insulin-like growth factor-I receptor-mediated migration and invasion and orthotopic tumor growth in mice. , 2005, Cancer research.
[85] F. Blasi. Urokinase and urokinase receptor: A paracrine/autocrine system regulating cell migration and invasiveness , 1993, BioEssays : news and reviews in molecular, cellular and developmental biology.
[86] A. Gown,et al. Monoclonal antibodies for detection of occult carcinoma cells in bone marrow of breast cancer patients , 1989, Cancer.
[87] H. Allgayer,et al. Immunocytochemical Phenotyping of Disseminated Tumor Cells in Bone Marrow by uPA Receptor and CK18: Investigation of Sensitivity and Specificity of an Immunogold/Alkaline Phosphatase Double Staining Protocol , 1997, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.
[88] H. Juhl,et al. Comparative analysis of bone marrow and venous blood isolates from gastrointestinal cancer patients for the detection of disseminated tumor cells using reverse transcription PCR. , 1997, Cancer research.
[89] M. Duffy,et al. Urokinase-type plasminogen activator and outcome in Dukes' B colorectal cancer , 1994, The Lancet.
[90] Kenneth M. Yamada,et al. Fibronectin at a glance , 2002, Journal of Cell Science.
[91] N. Brünner,et al. Urokinase and plasminogen activator inhibitor type 1 in pulmonary adenocarcinoma. , 1994, Cancer research.
[92] B. Nielsen,et al. The urokinase receptor as a potential target in cancer therapy. , 2004, Current pharmaceutical design.
[93] Lars Holmgren,et al. Dormancy of micrometastases: Balanced proliferation and apoptosis in the presence of angiogenesis suppression , 1995, Nature Medicine.
[94] J. Skibber,et al. Transcriptional activation of the urokinase receptor gene in invasive colon cancer , 1994, International journal of cancer.
[95] K. Danø,et al. Plasminogen activator inhibitor from human fibrosarcoma cells binds urokinase-type plasminogen activator, but not its proenzyme. , 1986, The Journal of biological chemistry.
[96] M. Speicher,et al. Comparative genomic hybridization, loss of heterozygosity, and DNA sequence analysis of single cells. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[97] L. Liotta,et al. Cancer metastasis and angiogenesis: An imbalance of positive and negative regulation , 1991, Cell.
[98] M. Kogo,et al. Inhibition of invasion and metastasis in oral cancer by targeting urokinase-type plasminogen activator receptor. , 2005, Oral Oncology.
[99] A. Niendorf,et al. Prognostic value of immunohistochemically identifiable tumor cells in lymph nodes of patients with completely resected esophageal cancer. , 1997, The New England journal of medicine.
[100] R. Cote,et al. Detection of Occult Bone Marrow Micrometastases in Patients with Operable Lung Carcinoma , 1995, Annals of surgery.
[101] D. Boyd,et al. The Kruppel-like KLF4 Transcription Factor, a Novel Regulator of Urokinase Receptor Expression, Drives Synthesis of This Binding Site in Colonic Crypt Luminal Surface Epithelial Cells* , 2004, Journal of Biological Chemistry.
[102] I. Mizukami,et al. cDNA for Mo3, a monocyte activation antigen, encodes the human receptor for urokinase plasminogen activator. , 1992, Journal of immunology.
[103] D. Cines,et al. Overexpression of urokinase receptor increases matrix invasion without altering cell migration in a human osteosarcoma cell line. , 1993, Cancer research.
[104] J. Köllermann,et al. Immunocytochemical detection of isolated tumour cells in bone marrow of patients with untreated stage C prostatic cancer. , 1995, European journal of cancer.
[105] H. Allgayer,et al. Tumor suppressor Pdcd4 inhibits invasion/intravasation and regulates urokinase receptor (u-PAR) gene expression via Sp-transcription factors , 2007, Oncogene.
[106] R. Scheuermann,et al. Cancer dormancy: Opportunities for new therapeutic approaches , 1997, Nature Medicine.
[107] R. Holle,et al. Micrometastatic breast cancer cells in bone marrow at primary surgery: prognostic value in comparison with nodal status. , 1996, Journal of the National Cancer Institute.
[108] K. Preissner,et al. Urokinase Receptor (CD87) Regulates Leukocyte Recruitment via β2 Integrins In Vivo , 1998, The Journal of experimental medicine.
[109] Christian Röder,et al. The detection of disseminated tumor cells in bone marrow from colorectal‐cancer patients by a cytokeratin‐20‐specific nested reverse‐transcriptase‐polymerase‐chain reaction is related to the stage of disease , 1996, International journal of cancer.
[110] B. Nielsen,et al. An alternatively spliced variant of mRNA for the human receptor for urokinase plasminogen activator , 1993, FEBS letters.
[111] K. Pantel,et al. Prognostic significance of bone marrow micrometastases in patients with gastric cancer. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[112] Klaus Pantel,et al. Molecular signature associated with bone marrow micrometastasis in human breast cancer. , 2003, Cancer research.
[113] H. Allgayer,et al. Urokinase system expression in gastric carcinoma , 2006, Cancer.
[114] H. Allgayer,et al. Individual development and uPA–receptor expression of disseminated tumour cells in bone marrow: A reference to early systemic disease in solid cancer , 1995, Nature Medicine.
[115] H. Nekarda,et al. Strong prognostic impact of tumor-associated urokinase-type plasminogen activator in completely resected adenocarcinoma of the esophagus. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.
[116] G Kvalheim,et al. Detection of isolated tumor cells in bone marrow is an independent prognostic factor in breast cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[117] S. Mandriota,et al. Vascular Endothelial Growth Factor Increases Urokinase Receptor Expression in Vascular Endothelial Cells (*) , 1995, The Journal of Biological Chemistry.
[118] G. Schlimok,et al. Prognostic significance of micrometastatic tumour cells in bone marrow of colorectal cancer patients , 1992, The Lancet.
[119] P. Jones,et al. Regulation of urokinase receptor transcription by Ras- and Rho-family GTPases. , 2000, Biochemical and biophysical research communications.
[120] C. Murray. Tumour dormancy: not so sleepy after all , 1995, Nature Medicine.
[121] D. Belin,et al. Concomitant secretion of prourokinase and of a plasminogen activator- specific inhibitor by cultured human monocytes-macrophages , 1984, The Journal of experimental medicine.
[122] J. Witte,et al. Monoclonal antibody therapy for resected Dukes' C colorectal cancer: seven-year outcome of a multicenter randomized trial. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[123] E. Appella,et al. Internalization of the urokinase-plasminogen activator inhibitor type-1 complex is mediated by the urokinase receptor. , 1992, The Journal of biological chemistry.
[124] P. Andreasen,et al. The plasminogen activation system in tumor growth, invasion, and metastasis , 2000, Cellular and Molecular Life Sciences CMLS.
[125] H. Allgayer,et al. Targeted disruption of the K-Ras oncogene in an invasive colon cancer cell line down-regulates urokinase receptor expression and plasminogen-dependent proteolysis , 1999, British Journal of Cancer.
[126] H. Allgayer. Molecular regulation of an invasion-related molecule--options for tumour staging and clinical strategies. , 2006, European journal of cancer.
[127] H. Verspaget,et al. Plasminogen activators in normal tissue and carcinomas of the human oesophagus and stomach. , 1993, Gut.
[128] J. Köllermann,et al. Comparative immunocytochemical assessment of isolated carcinoma cells in lymph nodes and bone marrow of patients with clinically localized prostate cancer , 1999, International journal of cancer.
[129] L. Ossowski,et al. Tumor Dormancy Induced by Downregulation of Urokinase Receptor in Human Carcinoma Involves Integrin and MAPK Signaling , 1999, The Journal of cell biology.
[130] L. Lund,et al. Transcriptional and post-transcriptional regulation of the receptor for urokinase-type plasminogen activator by cytokines and tumour promoters in the human lung carcinoma cell line A549. , 1995, The Biochemical journal.
[131] K. Pantel,et al. Detection and molecular characterisation of disseminated tumour cells: implications for anti-cancer therapy. , 2005, Biochimica et biophysica acta.
[132] M. Ploug,et al. Structural analysis of the interaction between urokinase-type plasminogen activator and its receptor: a potential target for anti-invasive cancer therapy. , 2001, Biochemical Society transactions.
[133] J. Köllermann,et al. Heterogeneous proliferative potential of occult metastatic cells in bone marrow of patients with solid epithelial tumors , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[134] K. Danø,et al. The Plasminogen Activation System in Human Colon Cancer : Messenger RNA for the Inhibitor PAI-1 Is Located in Endothelial Cells in the Tumor , 2006 .
[135] R. Scheuermann,et al. Cancer dormancy: isolation and characterization of dormant lymphoma cells. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[136] E. Lengyel,et al. β3A-Integrin Downregulates the Urokinase-Type Plasminogen Activator Receptor (u-PAR) through aPEA3/ets Transcriptional Silencing Element in the u-PAR Promoter , 2001, Molecular and Cellular Biology.
[137] J. Cajot,et al. The role of the urokinase receptor in extracellular matrix degradation by ht29 human colon carcinoma cells , 1993, International journal of cancer.
[138] V. Drewett,et al. The small-GTPase RalA activates transcription of the urokinase plasminogen activator receptor (uPAR) gene via an AP1-dependent mechanism , 2001, Oncogene.
[139] Bjørn Naume,et al. Circulating and disseminated tumor cells. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[140] A. Vaheri,et al. Ultrastructural localization of plasma membrane-associated urokinase- type plasminogen activator at focal contacts , 1988, The Journal of cell biology.
[141] E. Appella,et al. Cloning and expression of the receptor for human urokinase plasminogen activator, a central molecule in cell surface, plasmin dependent proteolysis. , 1990, The EMBO journal.
[142] M L Lesser,et al. Prediction of early relapse in patients with operable breast cancer by detection of occult bone marrow micrometastases. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[143] M. L. Le Beau,et al. Structure of the gene for human plasminogen activator inhibitor-2. The nearest mammalian homologue of chicken ovalbumin. , 1989, The Journal of biological chemistry.
[144] G. Schlimok,et al. Micrometastases of bone marrow in localized prostate cancer: correlation with established risk factors. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[145] B. Ljung,et al. The urokinase receptor is expressed in invasive breast cancer but not in normal breast tissue. , 1994, Cancer research.
[146] K. Danø,et al. Plasminogen activators, tissue degradation, and cancer. , 1985, Advances in cancer research.